找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Critical Care of COVID-19 in the Emergency Department; Joseph R. Shiber Book 2021 The Editor(s) (if applicable) and The Author(s), under e

[復(fù)制鏈接]
樓主: hormone-therapy
51#
發(fā)表于 2025-3-30 12:12:35 | 只看該作者
Point of Care Echocardiography in the COVID-19 Patient,ritically ill COVID-19 patient, facilitating early implementation of definitive therapy for a multitude of conditions associated with COVID-19 infection including thromboembolic disease, pleural effusion, pulmonary edema, and myocarditis. Through a protocolized approach to cleaning and disinfection,
52#
發(fā)表于 2025-3-30 14:52:05 | 只看該作者
Inter-Hospital Transfer of the Critically Ill COVID-19 Patient,tinued management of these patients may exceed the capacity or capability of the hospital to which the patient presented. Inter-facility transfer of a critically ill patient with COVID-19 may therefore be necessary. Multiple models for transfer of pediatric, ST-elevation myocardial infarction, and t
53#
發(fā)表于 2025-3-30 19:28:38 | 只看該作者
54#
發(fā)表于 2025-3-30 22:06:43 | 只看該作者
55#
發(fā)表于 2025-3-31 02:17:58 | 只看該作者
Management of Undifferentiated Critically Ill COVID-19 Patients,lly ill COVID-19 patients’ airway, breathing, and circulations (ABCs) is still paramount. This chapter reported recommendations from current literature regarding managing the undifferentiated critically ill COVID-19 patients. We also summarized our current knowledge regarding treatment for COVID-19.
56#
發(fā)表于 2025-3-31 06:03:47 | 只看該作者
57#
發(fā)表于 2025-3-31 11:25:27 | 只看該作者
58#
發(fā)表于 2025-3-31 14:07:02 | 只看該作者
Pharmacological Agents for COVID-19 Patients,entation. Current evidence will support corticosteroids, thromboprophylaxis, and remdesivir. Limited evidence exists around the monoclonal antibodies, at this time. Some treatment options are to be initiated earlier and in higher-risk patient populations to reduce progression to more severe disease and hospitalization.
59#
發(fā)表于 2025-3-31 19:22:13 | 只看該作者
60#
發(fā)表于 2025-4-1 00:05:32 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 15:51
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
章丘市| 宜昌市| 江川县| 安龙县| 德惠市| 鸡东县| 许昌市| 汉沽区| 南召县| 齐齐哈尔市| 绥德县| 奉节县| 泰来县| 渑池县| 禄劝| 清流县| 溆浦县| 甘洛县| 通州区| 宝山区| 晋江市| 台州市| 京山县| 大足县| 荣昌县| 高安市| 浙江省| 夏邑县| 尚义县| 屏东县| 竹北市| 乌鲁木齐市| 项城市| 专栏| 鄯善县| 天峻县| 剑阁县| 宾阳县| 宁津县| 清水河县| 德格县|